Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2016 08; 22(8):1440-1448.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents, Immunological
Cyclophosphamide
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Follicular
Middle Aged
Myeloablative Agonists
Recurrence
Remission Induction
Rituximab
Salvage Therapy
Survival Analysis
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome
Vidarabine

authors with profiles

CHITRA HOSING